Immunexpress Group's Grant

Immunexpress Group raised a round of funding on February 18, 2014. Investors include Commercialisation Australia.

Immunexpress is a molecular diagnostic company committed to improving outcomes for patients with, and, at risk of, sepsis. The core competency of Immunexpress is the clinical validation of genomic and…

Articles about Immunexpress Group's Grant: